Today: 12 May 2026
Plug Power stock rises as UBS conference nears and Jan. 29 vote raises reverse-split stakes
12 January 2026
1 min read

Plug Power stock rises as UBS conference nears and Jan. 29 vote raises reverse-split stakes

New York, Jan 12, 2026, 11:01 ET — Regular session

  • Plug Power shares rose 4.1% to $2.28, while the broader market edged down slightly
  • Management will present at the UBS energy conference this Monday
  • Company warns it will seek a reverse stock split if shareholders turn down the proposal to increase authorized shares

Plug Power Inc (PLUG) shares climbed 4.1% to $2.28 by late morning on Monday, trading in a range from $2.14 up to $2.30. Roughly 28.4 million shares changed hands.

Investors are zeroing in on Plug’s special meeting set for Jan. 29, where shareholders will vote on key charter amendments — notably raising authorized common shares from 1.5 billion to 3.0 billion. Plug warned that if the increase fails, it “will implement a reverse stock split” to free up shares needed to meet financial commitments and maintain operational flexibility. Back in November, then-CEO Andy Marsh described these changes as “essential” to guarantee Plug has the “resources and flexibility” to carry out its strategy. Plug Power

Plug executives Jose Luis Crespo and investor relations chief Roberto Friedlander will take part in UBS’s Global Energy & Utilities Winter Conference on Monday, the company’s events calendar shows.

Authorized shares set the maximum number of shares a company can issue according to its charter. A reverse stock split reduces the number of shares outstanding, which can create space for issuing more stock down the line, but it often unsettles investors since the share count drops sharply overnight.

Last week, Plug revealed adjustments to its longstanding deal with Walmart. According to a regulatory filing, Plug inked a “Release Event License Agreement” granting Walmart conditional, limited access to some escrowed GenKey-system materials— but only if certain “release events” happen. Walmart also agreed to terminate a 2017 transaction agreement linked to a warrant. Plug noted this step removes the risk of diluting roughly 42.2 million shares down the line.

The exhibit revealed that the contract’s definition of “release events” covers bankruptcy-related triggers along with other disruptions connected to the GenKey system.

Plug’s gains didn’t carry over to its fuel-cell peers. Bloom Energy slipped roughly 1.4%, FuelCell Energy edged down 0.3%, and Ballard Power barely moved. The S&P 500 ETF dipped around 0.1%.

The setup works both ways. Approving a higher share cap would give Plug more flexibility to raise funds, but it also opens the door to easier dilution. If rejected, attention could shift to a reverse split and how the company plans to handle its short-term financing needs.

Coming up: any insights from management’s UBS appearance and the shareholder vote set for Jan. 29 at 10:00 a.m. ET, streamed live via webcast.

Stock Market Today

  • Wall Street Dips as CPI Rises and Middle East Tensions Elevate Oil Prices
    May 12, 2026, 11:58 AM EDT. Wall Street's main indexes slipped on Tuesday, with the S&P 500 and Nasdaq retreating from record highs. The U.S. Consumer Price Index (CPI) rose 3.8% annually in April, surpassing the 3.7% forecast and marking the highest inflation rate in nearly three years. This fuels expectations that the Federal Reserve will maintain steady interest rates longer. Heightened tensions between the U.S. and Iran, with no ceasefire in sight and the Strait of Hormuz closed, have kept oil prices high, adding to inflation fears. The Dow fell 0.60%, S&P 500 dropped 0.57%, and Nasdaq lost 0.92%. Consumer discretionary stocks led losses. Despite strong earnings, concerns persist on inflation and geopolitical risks, overshadowing optimism from AI and corporate earnings momentum.

Latest article

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

Hims & Hers’ GLP-1 Reset Hits the Stock as Investors Reprice Growth Quality

12 May 2026
Hims & Hers Health shares fell 14.6% to $24.89 Tuesday after a Q1 net loss of $92.1 million, reversing a $49.5 million profit a year ago. Revenue rose 4% to $608.1 million, but gross margin dropped to 65% from 73% as the company shifted from compounded GLP-1s to branded drugs like Wegovy and Ozempic. Subscribers climbed to 2.584 million, while monthly revenue per subscriber slipped to $80.
POET Stock Rebounds as New COO Gives AI-Photonics Rally a Fresh Test

POET Stock Rebounds as New COO Gives AI-Photonics Rally a Fresh Test

12 May 2026
POET Technologies named Sandeep Kumar as chief operating officer, triggering a 2.95% stock rise to $14.31 on heavy volume after shares hit $15.15 intraday. Kumar, formerly of Silicon Labs, will oversee Malaysia manufacturing as the company targets high-volume production. The move comes after Marvell canceled Celestial AI orders, which had weighed on the stock. Broader tech indices fell Tuesday, but POET shares outperformed.
IREN Stock Slips as Nvidia Deal Runs Into the Price of Building AI Capacity

IREN Stock Slips as Nvidia Deal Runs Into the Price of Building AI Capacity

12 May 2026
IREN shares fell about 2.4% to $53.80 Tuesday after the company priced an upsized $2.6 billion convertible-note sale, raising concerns over funding costs and dilution. The notes carry a 1% coupon and can convert at $73.07 per share. IREN reported a $247.8 million net loss last quarter. Peers Cipher Digital, Riot Platforms, and Marathon Digital also traded lower.

Popular

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

11 November 2025
Pfizer will acquire Metsera for up to $10 billion, offering $65.60 per share in cash plus contingent value rights, with a shareholder vote set for Nov. 13. Metsera’s board favored Pfizer over Novo Nordisk after FTC antitrust concerns tipped the balance. Pfizer shares rose about 4–5% to $25.50 following the news. The company also announced seven new trials for its PD‑1×VEGF bispecific antibody, including a phase 3 lung cancer study.
Oracle stock ticks up as Goldman turns bullish; new retail AI supply-chain tool adds focus
Previous Story

Oracle stock ticks up as Goldman turns bullish; new retail AI supply-chain tool adds focus

Vistra stock jumps as VST taps debt markets; analysts recalibrate after Meta nuclear pact
Next Story

Vistra stock jumps as VST taps debt markets; analysts recalibrate after Meta nuclear pact

Go toTop